← Insulin × glycemic control

TrialDiabetes, obesity & metabolism2019

Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.

Athena Philis-Tsimikas et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 210 people · 2019

Not counted

Probably lowered glycemic control

−3.90mmol/mol−5.45 to −2.35

As reported

difference −3.90 mmol/mol, 95% CI −5.45 to −2.35

Not counted

Probably lowered body weight & composition

−1.92kg−2.64 to −1.19

As reported

difference −1.92 kg, 95% CI −2.64 to −1.19

Not counted

Probably lowered glycemic control

−58%−77% to −25%

Bigger than 7 in 10 for glycemic control

As reported

IRR 0.42, 95% CI 0.23–0.75

Three numbers in the abstract

the abstract, start to end

… of IDegLira (difference in HbA1c change -3.90 mmol/mol; 95% confidence …

… confirmed for: body weight (difference -1.92 kg; 95% CI -2.64, -1.19); severe or blood-glucose-confirmed symptomatic hypoglycaemia (rate ratio 0.42; 95% CI 0.23, 0.75); total …

← favours treatmentfavours comparator →
could be chance
Glycemic control
−3.90−5.45 to −2.35
Body weight & composition
−1.92−2.64 to −1.19
Glycemic control
IRR 0.420.23–0.75
InsulinGlycemic controlBody weight & composition
1 / 3

46 papers cite it

2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT02773368phase 3420 enrolled2016
Full record →Abstract, authors, funding and every citing paper · PMID 30761720